Table 2 Patients’ characteristics and treatment outcomes according to subgroups
Subgroup 1 | Subgroup 2 | Subgroup 3 | Subgroup 4 | |
|---|---|---|---|---|
Treatment type Patients, n | CHT 11 | Rituximab + CHT 20 | Rituximab + CHT + RT 37 | CHT + RT 30 |
Male: female Stage I-II Stage III-IV B-symptoms LDH elevation SVC syndrome | 4: 7 5 (45.5%) 6 (54.5%) 7 (63.6%) 5 (45.5%) 7 (63.6%) | 7: 13 9 (45.0%) 11 (55.0%) 10 (50.0%) 5 (25.0%) 7 (35.0%) | 19: 18 34 (91.9%) 3 (8.1%) 10 (27.0%) 3 (8.1%) 13 (35.1%) | 10: 20 23 (76.7%) 7 (23.3%) 14 (46.7%) 12 (40.0%) 16 (53.3%) |
ORR CR PR SD PD | 90.9% 6 (54.5%) 4 (36.4%) 1 (9.1%) 0 | 55.0% 9 (45.0%) 2 (10.0%) 0 9 (45.0%) | 100% 37 (100%) 0 0 0 | 100% 30 (100%) 0 0 0 |
Relapse/Progress. Deaths | 2 (18.2%) 2 (18.2%) | 3 (15.0%) 7 (35.0%) | 2 (5.4%) 2 (5.4%) | 4 (13.3%) 4 (13.3%) |
9 years OS (a) 9 years PFS (a) 5 years DFS | 80.0% 63.6% 66.7% | 62.3% 45.0% 90.0% | 93.6% 94.4% 94.4% | 92.2% 86.5% 86.5% |